| Drug Name |
Adalimumab |
| Drug ID |
BADD_D00041 |
| Description |
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799]. |
| Indications and Usage |
For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. |
| Marketing Status |
Prescription |
| ATC Code |
L04AB04 |
| DrugBank ID |
DB00051
|
| KEGG ID |
D02597
|
| MeSH ID |
D000068879
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0K5KS
|
| NDC Product Code |
0074-0616; 0074-0243; 0074-1115; 0074-1117; 0074-2540; 0074-4339; 0074-0817; 0074-3799; 0074-0067; 0074-0554; 0074-1539; 50090-4487; 0074-2330; 69438-0003; 0074-0124; 58394-051 |
| Synonyms |
Adalimumab | Humira | Adalimumab-adbm | Amjevita | Adalimumab-atto | Cyltezo | D2E7 Antibody | Antibody, D2E7 |
